View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
April 17, 2020

Gilead’s remdesivir shows promise in Covid-19 trial

Gilead Sciences’ antiviral drug candidate remdesivir has led to quick recoveries in symptoms of Covid-19 patients in a clinical trial, according to a report by STAT news agency.

STAT is said to have obtained a copy of a video discussion by a University of Chicago faculty member overseeing the study.

According to the partial data reported, participants treated with remdesivir experienced rapid recoveries in fever and respiratory symptoms and nearly all patients were discharged within one week.

Read the full article here

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena